HER2-Low Tumors — Deal Benchmarks & Valuation
Market Analysis
HER2-Low Tumors is one of the most actively transacted indications in oncology licensing. Phase 2 deals for her2-low tumors carry a median total deal value of $2.0B, with upfront payments ranging from $178M to $451M. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones.
Milestone structures for her2-low tumors deals allocate $427M to development milestones, $682M to regulatory milestones, and $597M to commercial milestones. Royalty rates range from 12.6% to 20.6% at the base tier, with tiered escalation reaching 16.6%-24.6% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for her2-low tumors licensing?
What royalty rates are standard for her2-low tumors deals?
How are her2-low tumors deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.